Clinical Trials

50 enrolled

Lymphoma, Lymphoma, B-Cell

NCT05598268 2022-10-28

A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.

GastrointestinalLymphoidOther solid neoplasmThoracic

74 enrolled

Mesothelioma, Malignant, Liver Neoplasms, Lung Neoplasms, Lymphoma

NCT05227898 2022-10-25

RESTORE

BreastGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmThoracic

352 enrolled

Breast Neoplasms, Colonic Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT03789617 2022-07-11

A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies

72 enrolled

GastrointestinalLymphoid

Adenocarcinoma Of Esophagus, Lymphoma, Stomach Neoplasms

NCT05446688 2022-07-07

A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma

Phase 2 Unknown

40 enrolled

Lymphoma

NCT05374226 2022-05-16

A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas

172 enrolled

Lymphoma

NCT05293028 2022-03-23

Study of F527 in Patients With Relapsed or Refractory Lymphoma

82 enrolled

Lymphoma

NCT05049083 2022-01-14

A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects

28 enrolled

Lymphoma

NCT05155215 2021-12-13

Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma

68 enrolled

Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, Mantle-Cell

NCT04818372 2021-11-12

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

87 enrolled

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT00003337 2021-08-16

Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma

Phase 3 Unknown

100 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00003338 2021-08-16

Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma

Phase 2/3 Unknown

60 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03374007 2021-08-16

GB226

72 enrolled

Hodgkin Disease, Lymphoma

NCT04458389 2021-08-13

A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas

268 enrolled

Lymphoma, Recurrence

NCT04934774 2021-06-22

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

20 enrolled

Lymphoma, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03852823 2021-04-30

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

GynecologicLymphoidOther solid neoplasmThoracic

192 enrolled

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Lymphoma

NCT04594135 2021-03-02

CD5CAR-T

20 enrolled

Lymphoma, Leukemia, T-Cell, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02546739 2021-01-26

Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL

100 enrolled

Leukemia, Lymphoma

NCT03271515 2021-01-20

Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL

20 enrolled

Leukemia, Lymphoma

NCT04480788 2021-01-06

CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study

9 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT04610125 2020-10-30

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

30 enrolled

Leukemia, Lymphoma

NCT03921879 2020-10-23

Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

50 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT04497701 2020-08-04

Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies

139 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Leukemia, Lymphoma

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04163575 2019-12-23

Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL

100 enrolled

Leukemia, Lymphoma

NCT03638206 2019-12-11

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

73 enrolled

Burkitt Lymphoma, Carcinoma, Renal Cell, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Leukemia, Myeloid, Lung Neoplasms, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Colorectal Neoplasms

NCT04156178 2019-11-12

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

Phase EARLY_PHASE1 Unknown

12 enrolled

Leukemia, Lymphoma, Leukemia, B-Cell, Lymphoma, B-Cell

NCT03821363 2019-01-29

Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymphoma

206 enrolled

Lymphoma, Neoplasms

NCT03312205 2019-01-09

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

50 enrolled

Disease, Leukemia, Lymphoma

NCT03488160 2018-04-10

CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma

6 enrolled

Lymphoma

NCT02656147 2017-09-05

Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL

48 enrolled

Leukemia, Lymphoma

NCT03121625 2017-04-25

CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

30 enrolled

Leukemia, Lymphoma

NCT02728882 2017-03-23

EECBL

24 enrolled

Lymphoma

NCT03086954 2017-03-22

EECPL

24 enrolled

Lymphoma

NCT02544724 2016-08-03

NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy

Phase 2 Unknown

12 enrolled